Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
NCT00257881
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
46
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
CMD-193
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer